Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meningococcal group ACYW135 conjugate vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal group ACYW135 conjugate vaccine is a quadrivalent conjugate vaccine designed to provide active immunization against invasive disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. The vaccine contains oligosaccharides from the bacterial capsules of these four serogroups that are chemically linked (conjugated) to a carrier protein such as diphtheria toxoid or CRM197. This conjugation enhances the immune response by promoting T-cell dependent immunity and immunological memory. The primary indication is prevention of meningitis and septicemia caused by these serogroups in children (as young as 2 months), adolescents, and adults up to 55 years old. Several brands are available globally; for example, Menveo uses CRM197 as the carrier protein[6][7][8]. The vaccines do not protect against *Neisseria meningitidis* serogroup B.
- Brand names
- MenveoMenactraNimenrix
- Other names
- MenACWY vaccinemeningococcal quadrivalent conjugate vaccineMen-C-ACYW-135Men-C-ACYW135Men-C-ACYW 135
02
Targets
Neuraminidase
Beyond the preview
Go deeper on Meningococcal group ACYW135 conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meningococcal group ACYW135 conjugate vaccine.